New breakthrough can effectively deliver medications into the brain
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
List view / Grid view
News
First-in-class migraine treatment approved by FDA
Reyvow (lasmiditan), for the treatment of acute migraine, has received approval from the FDA following success in clinical trials.
XARELTO® approved to help prevent blood clots
The FDA has approved XARELTO® (rivaroxaban) to help prevent blood clots in acutely ill medical patients.
Clinical trial to investigate the use of CBD for Parkinson’s-related psychosis
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
DRC to use a second Ebola vaccine by November
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
UK government signs contracts for medicine freight capacity
Four companies have agreed with the UK government to deliver medicines to the country after Brexit, signing contracts worth £86.6 million.
Sterile compounded drug products voluntarily recalled
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Discover Nemera’s innovative technologies and end-to-end development offerings at booth 111C52
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health, including off-the-shelf innovative systems, customized design development and GMP contract manufacturing.
Breakthrough Therapy Designation granted to treatment for IDLs
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
DHSC supports continuity of medical supplies in a no-deal Brexit scenario
The Secretary of State for Health and Social Care is supporting the continuity of medical supplies if the UK is to leave the EU without a deal.
AI can predict which research will translate to clinical trials
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
Pharmaceutical product development within the Fujifilm Group
Custom manufacturing of specialty chemicals and APIs.
Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
Clinical trial shows cell therapy could be safe for liver disease patients
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
